Clinical stage biotech Arsanis (Nasdaq: ASNS) lost 78% of its market value on Thursday amid news that it is to halt a Phase II trial of its pneumonia candidate, ASN100.
The USA-headquartered company, which is focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, made the announcement following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC).
"Arsanis remains confident in the potential of monoclonal antibodies to prevent and treat serious infections"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze